Following the establishment of adjuvant chemotherapy as the standard of care option in locally advanced NSCLC, evidence towards increased benefit from other adjuvant therapies in NSCLC were lacking for more than 15 years until the ADAURA trial, which reported improved outcomes with the adjuvant use of osimertinib in those with EGFR positive NSCLC [45]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.